NPM1 and acute myeloid leukemia: Recently, Syndex Pharmaceuticals announced the results of phase II of the AUGMENT-001 study evaluating the efficacy of Revumenib in 64 R/R heavily pretreated (75% relapsing after Ventoclax therapy) NPM1-mutated AML patients: 23% of the patients achieved CR + CRi; the ORR was 47%; the MRD negativity was 64% among the patients who achieved CR + CRi; and 17% of the responding patients underwent HSCT [103].